|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NRSN2 |
Gene summary for NRSN2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NRSN2 | Gene ID | 80023 |
| Gene name | neurensin 2 | |
| Gene Alias | C20orf98 | |
| Cytomap | 20p13 | |
| Gene Type | protein-coding | GO ID | GO:0007275 | UniProtAcc | Q9GZP1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80023 | NRSN2 | P27T-E | Human | Esophagus | ESCC | 1.88e-11 | 1.97e-01 | 0.1055 |
| 80023 | NRSN2 | P28T-E | Human | Esophagus | ESCC | 3.28e-14 | 2.09e-01 | 0.1149 |
| 80023 | NRSN2 | P30T-E | Human | Esophagus | ESCC | 2.59e-11 | 3.70e-01 | 0.137 |
| 80023 | NRSN2 | P31T-E | Human | Esophagus | ESCC | 9.67e-18 | 3.40e-01 | 0.1251 |
| 80023 | NRSN2 | P32T-E | Human | Esophagus | ESCC | 1.90e-21 | 4.64e-01 | 0.1666 |
| 80023 | NRSN2 | P36T-E | Human | Esophagus | ESCC | 5.51e-08 | 4.01e-01 | 0.1187 |
| 80023 | NRSN2 | P37T-E | Human | Esophagus | ESCC | 7.89e-07 | 1.82e-01 | 0.1371 |
| 80023 | NRSN2 | P38T-E | Human | Esophagus | ESCC | 6.79e-03 | 1.23e-01 | 0.127 |
| 80023 | NRSN2 | P40T-E | Human | Esophagus | ESCC | 2.76e-10 | 2.86e-01 | 0.109 |
| 80023 | NRSN2 | P42T-E | Human | Esophagus | ESCC | 2.63e-09 | 1.72e-01 | 0.1175 |
| 80023 | NRSN2 | P47T-E | Human | Esophagus | ESCC | 1.88e-11 | 1.88e-01 | 0.1067 |
| 80023 | NRSN2 | P48T-E | Human | Esophagus | ESCC | 1.76e-12 | 1.98e-01 | 0.0959 |
| 80023 | NRSN2 | P49T-E | Human | Esophagus | ESCC | 1.42e-18 | 9.97e-01 | 0.1768 |
| 80023 | NRSN2 | P52T-E | Human | Esophagus | ESCC | 2.27e-21 | 3.69e-01 | 0.1555 |
| 80023 | NRSN2 | P56T-E | Human | Esophagus | ESCC | 4.34e-05 | 9.24e-01 | 0.1613 |
| 80023 | NRSN2 | P57T-E | Human | Esophagus | ESCC | 6.62e-20 | 3.83e-01 | 0.0926 |
| 80023 | NRSN2 | P61T-E | Human | Esophagus | ESCC | 1.71e-13 | 2.59e-01 | 0.099 |
| 80023 | NRSN2 | P62T-E | Human | Esophagus | ESCC | 4.73e-11 | 2.41e-01 | 0.1302 |
| 80023 | NRSN2 | P65T-E | Human | Esophagus | ESCC | 8.20e-17 | 3.64e-01 | 0.0978 |
| 80023 | NRSN2 | P74T-E | Human | Esophagus | ESCC | 9.80e-25 | 6.43e-01 | 0.1479 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NRSN2 | SNV | Missense_Mutation | rs780211474 | c.164G>A | p.Arg55Gln | p.R55Q | Q9GZP1 | protein_coding | tolerated(0.67) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| NRSN2 | insertion | Nonsense_Mutation | novel | c.364_365insCTCAGGATTCCAAATAAAACATGACAG | p.Leu122delinsProGlnAspSerLysTerAsnMetThrVal | p.L122delinsPQDSK*NMTV | Q9GZP1 | protein_coding | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD | ||
| NRSN2 | SNV | Missense_Mutation | novel | c.314N>T | p.Ala105Val | p.A105V | Q9GZP1 | protein_coding | tolerated(0.16) | benign(0.12) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NRSN2 | SNV | Missense_Mutation | c.316N>T | p.Ala106Ser | p.A106S | Q9GZP1 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
| NRSN2 | SNV | Missense_Mutation | c.547T>C | p.Phe183Leu | p.F183L | Q9GZP1 | protein_coding | tolerated(0.51) | benign(0.001) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NRSN2 | SNV | Missense_Mutation | rs139750306 | c.161N>A | p.Arg54His | p.R54H | Q9GZP1 | protein_coding | tolerated(0.81) | benign(0) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| NRSN2 | SNV | Missense_Mutation | rs527857076 | c.310N>T | p.Arg104Trp | p.R104W | Q9GZP1 | protein_coding | deleterious(0.01) | possibly_damaging(0.707) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NRSN2 | SNV | Missense_Mutation | rs145813295 | c.466N>A | p.Asp156Asn | p.D156N | Q9GZP1 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NRSN2 | SNV | Missense_Mutation | rs372152096 | c.559G>A | p.Ala187Thr | p.A187T | Q9GZP1 | protein_coding | tolerated(0.76) | benign(0) | TCGA-AP-A1DR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| NRSN2 | SNV | Missense_Mutation | novel | c.590C>T | p.Thr197Ile | p.T197I | Q9GZP1 | protein_coding | deleterious(0.05) | probably_damaging(0.956) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |